Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring - Tập 8 - Trang 1-10 - 2017
Alain D. Dekker1,2, Juan Fortea3,4, Rafael Blesa3, Peter P. De Deyn1,2
1Department of Neurology and Alzheimer Research Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
2Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium
3Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
4Down Medical Center, Catalan Down Syndrome Foundation, Barcelona, Spain

Tóm tắt

AbstractDown syndrome (DS), present in nearly six million people, is associated with an extremely high risk to develop Alzheimer's disease (AD). Amyloid‐β and tau pathology are omnipresent from age 40 years onward, but clinical symptoms do not appear in all DS individuals. Dementia diagnostics is complex in this population, illustrating the great need for predictive biomarkers. Although blood biomarkers have not yet proven useful, cerebrospinal fluid (CSF) biomarkers (low amyloid‐β42, high t‐tau, and high p‐tau) effectively contribute to AD diagnoses in the general population and are increasingly used in clinical practice. Surprisingly, CSF biomarkers have been barely evaluated in DS. Breaking the taboo on CSF analyses would finally allow for the elucidation of its utility in (differential) diagnoses and staging of disease severity. A sensitive and specific biomarker profile for AD in DS would be of paramount importance to daily care, adaptive caregiving, and specific therapeutic interventions.

Tài liệu tham khảo

10.1016/S1474-4422(16)00063-6 10.1093/eurpub/ckl103 10.1038/nrn3983 Alzheimer's Assocation, 2016, 2016 Alzheimer's disease facts and figures, Alzheimers Dement, 12, 459, 10.1016/j.jalz.2016.03.001 10.1002/ajhb.10132 10.1006/nbdi.1996.0003 10.1111/j.1365-2559.1988.tb02018.x 10.1212/WNL.56.7.979 10.1002/ana.410430316 10.1016/j.cortex.2015.07.032 10.1352/2008.46:215-228 10.1111/j.1365-2788.2000.00305.x Livingstone N., 2015, Pharmacological interventions for cognitive decline in people with Down syndrome, Cochrane Database Syst Rev, CD011546 10.1111/j.1365-2788.2007.01036.x Nowrangi M.A., 2015, Principles and management of neuropsychiatric symptoms in Alzheimer's dementia, Alzheimers Res Ther, 7, 1, 10.1186/s13195-015-0096-3 10.1038/nature19323 10.1016/j.jalz.2012.05.2116 10.1016/j.jalz.2014.02.004 De Deyn P.P., 2015, Dementia: cerebrospinal fluid biomarkers in dementias, Nat Rev Neurol, 11, 549, 10.1038/nrneurol.2015.175 10.1093/brain/awv181 10.1016/j.neurobiolaging.2007.02.016 10.1212/WNL.0b013e31823ed0f0 10.3233/JAD-140240 10.1016/j.jalz.2011.03.004 10.1016/j.jalz.2011.03.005 10.1016/j.jalz.2015.08.003 10.1111/j.1468-1331.2010.03040.x 10.1016/j.jalz.2014.05.1753 10.1373/clinchem.2014.236679 10.1002/1531-8249(199912)46:6<933::AID-ANA20>3.0.CO;2-4 10.1159/000109215 10.1159/000358800 10.1021/pr050475v 10.1212/WNL.50.1.169 10.1007/s12017-014-8302-1 10.1016/j.jalz.2014.10.007 Wark S., 2014, Down syndrome and dementia: is depression a confounder for accurate diagnosis and treatment?, J Intellect Disabil, 18, 305, 10.1177/1744629514552152 10.1016/j.clineuro.2004.10.011 10.2174/156720509788486509 10.3233/JAD-131334 10.3233/JAD-160827 10.1016/j.neurobiolaging.2011.08.007 10.1097/NEN.0b013e31803d3ae4 10.1016/j.neuint.2009.08.006 AC Immune SA. A Phase Ib Multi‐Center Double‐Blind Randomized Placebo‐Controlled Dose Escalation Study of the safety tolerability and immunogenicity of ACI‐24 in adults with Down syndrome. Clin Identifier NCT02738450 2016. Available at:https://clinicaltrials.gov/ct2/show/study/NCT02738450?term=Trisomy+21+AND+CSF&rank=1. Accessed January 5 2017. University of Colorado Denver. Rocky Mountain Alzheimer's Disease Center at the University of Colorado School of Medicine (RMADC at UCSOM) Longitudinal Biomarker and Clinical Phenotyping Study. Clin Identifier NCT02612376 2015. Available at:https://clinicaltrials.gov/ct2/show/study/NCT02612376?term=Trisomy+21+AND+CSF&rank=2. Accessed January 5 2017. 10.3389/fnbeh.2015.00239 10.1093/brain/aww015 10.3988/jcn.2016.12.4.381 10.1002/ana.410210416 Schapiro M.B., 1987, Cerebrospinal fluid monoamines in Down's syndrome adults at different ages, J Ment Defic Res, 31, 259 10.1111/j.1600-0404.1984.tb07817.x Atack J.R., 1998, Cerebrospinal fluid production is normal in Down syndrome, Neurobiol Aging, 19, 307, 10.1016/S0197-4580(98)00069-4 10.1016/j.jalz.2016.06.713 Aalten P., 2014, The Dutch Parelsnoer Institute—neurodegenerative diseases; methods, design and baseline results, BMC Neurol, 14, 254, 10.1186/s12883-014-0254-4 10.3233/JAD-140783 10.1016/j.jalz.2013.05.1775 10.1155/2012/170276 10.1016/j.jalz.2016.05.001 10.3233/JAD-142514 10.1016/j.neubiorev.2014.05.004 10.1038/tp.2014.61 10.3233/JAD-140795
Thông tin
Thông tin xuất bản

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

Tập 8

1-10

Thông tin tác giả